Science Explorer Back to mapMap

Most cited papers from Coastal Health District

What are the most cited papers from Coastal Health District?

The most cited paper from Coastal Health District is "Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial" (David A. Margolis, Cynthia C Brinson, Graham H.R. Smith et al., 2015), with 205 citations. Next come "Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial" (169) and "Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials" (144).

Showing 50 of 59 papers. Every paper is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial David A. Margolis, Cynthia C Brinson, Graham H.R. Smith et al. · The Lancet Infectious Diseases 19 Jul 2015 205
2 Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial David Alain Wohl, Yazdan Yazdanpanah, Axel Baumgarten et al. · The Lancet HIV 8 May 2019 169
3 Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials Chloe M. Orkin et al. · The Lancet HIV Open access Jun 2020 144
4 Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study Catherine Orrell et al. · The Lancet HIV 106 authors 18 Jul 2017 118
5 Sex-Based Outcomes of Darunavir–Ritonavir Therapy Judith S. Currier, Dawn Averitt Bridge, Debbie Hagins et al. · Annals of Internal Medicine Open access 21 Sep 2010 85
6 Integrase inhibitor versus protease inhibitor based regimen for HIV-1 infected women (WAVES): a randomised, controlled, double-blind, phase 3 study Kathleen Squires, Cissy M Kityo, Sally Hodder et al. · The Lancet HIV Open access 29 May 2016 84
7 Dolutegravir versus Placebo in Subjects Harbouring HIV-1 with Integrase Inhibitor Resistance Associated Substitutions: 48-Week Results from VIKING-4, a Randomized Study Bisher Akil, Gary Blick, Debbie P. Hagins et al. · Antiviral Therapy Apr 2014 80
8 Health effects of long-term mercury exposure among chloralkali plant workers Howard Frumkin, Richard Letz, Phillip L. Williams et al. · American Journal of Industrial Medicine 2001 77
9 Forty‐eight‐week efficacy and safety and early CNS tolerability of doravirine (MK‐1439), a novel NNRTI, with TDF/FTC in ART‐naive HIV‐positive patients Josep M. Gatell, Javier O Morales‐Ramirez, Debbie P. Hagins et al. · Journal of the International AIDS Society Open access Nov 2014 60
10 Switching to Fixed-Dose Bictegravir, Emtricitabine, and Tenofovir Alafenamide (B/F/TAF) in Virologically Suppressed HIV-1 Infected Women: A Randomized, Open-Label, Multicenter, Active-Controlled, Phase 3, Noninferiority Trial Cissy M Kityo, Debbie P. Hagins, Ellen Koenig et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes Open access 14 Oct 2019 58
11 A systematic review on the effectiveness of diet and exercise in the management of obesity Iyanu Victoria Olateju, Taiwo Opaleye-Enakhimion, Jennifer E. Udeogu et al. · Diabetes & Metabolic Syndrome Clinical Research & Reviews Review Apr 2023 52
12 Recruitment and Retention of Diverse Populations in Antiretroviral Clinical Trials: Practical Applications from the Gender, Race And Clinical Experience Study Ron Falcon, Dawn Averitt Bridge, Judith S. Currier et al. · Journal of Women s Health Open access 10 Jun 2011 49
13 Objective Evidence of Reflux Control After Magnetic Sphincter Augmentation Brian E. Louie, C. Daniel Smith, Christopher C. Smith et al. · Annals of Surgery 24 Apr 2018 48
14 Switching to coformulated rilpivirine ( RPV ), emtricitabine ( FTC ) and tenofovir alafenamide from either RPV , FTC and tenofovir disoproxil fumarate ( TDF ) or efavirenz, FTC and TDF : 96‐week results from two randomized clinical trials D Hagins, Chloe M. Orkin, ES Daar et al. · HIV Medicine Open access 12 Aug 2018 47
15 Early detection and prevention of lung cancer Gail Shaw Wright, Michael E. Gruidl · Current Opinion in Oncology Mar 2000 45
16 Peripheral nerves are pathologically small in cerebellar ataxia neuropathy vestibular areflexia syndrome: a controlled ultrasound study Luciana Pelosi, Eoin Mulroy, Ruth Leadbetter et al. · European Journal of Neurology 10 Jan 2018 44
17 Communicating about Youth’s Sun Exposure Risk to Soccer Coaches and Parents: A Pilot Study in Georgia Roxanne L Parrott, Ashley Paige Duggan, Jeff Cremo et al. · Health Education & Behavior Jun 1999 41
18 Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trial Anthony Mills, Giuliano Rizzardini, Moti N. Ramgopal et al. · The Lancet HIV 8 May 2024 35
19 Pharmacokinetics and antiviral activity of cabotegravir and rilpivirine in cerebrospinal fluid following long-acting injectable administration in HIV-infected adults Scott Lee Letendre, Anthony Mills, Debbie P. Hagins et al. · Journal of Antimicrobial Chemotherapy Open access 22 Nov 2019 32
20 Outbreak of Tuberculosis Associated with a Floating Card Game in the Rural South: Lessons for Tuberculosis Contact Investigations NAOMI N. BOCK, John P. Mallory, Nell Mobley et al. · Clinical Infectious Diseases Open access Nov 1998 31
21 A Cost‐effectiveness Analysis of Propofol versus Midazolam for Procedural Sedation in the Emergency Department Corinne Michèle Hohl, Bohdan Nosyk, Mohsen Sadatsafavi et al. · Academic Emergency Medicine Open access 2008 31
22 Audit of severe acute maternal morbidity describing reasons for transfer and potential preventability of admissions to ICU Beverley A. LAWTON, Leona Wilson, Richard Dinsdale et al. · Australian and New Zealand Journal of Obstetrics and Gynaecology 28 Jul 2010 30
23 Solarization and Chemical Alternatives to Methyl Bromide for Preplant Soil Treatment of Strawberries Mark W. Rieger, Gerard W. Krewer, Pamela M. Lewis · HortTechnology Open access 2001 28
24 Doravirine dose Selection and 96-Week Safety and Efficacy versus Efavirenz in Antiretroviral Therapy-Naive Adults with HIV-1 Infection in a Phase IIb Trial José M. Gatell et al. · Antiviral Therapy Aug 2018 25
25 An evaluation of “groups for parents” a standardized format encompassing both behavior modification and humanistic methods Orin W. Sadler, Terence Seyden, Billy Howe et al. · Journal of Community Psychology Apr 1976 19
26 Brief Report: Efficacy and Safety of Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide (E/C/F/TAF) in Virologically Suppressed Women Sally Hodder, Kathleen Squires, Cissy M Kityo et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes Open access 23 Feb 2018 18
27 Recommendations and Administration of the HPV Vaccine to 11- to 12-Year-Old Girls and Boys John S. Luque, Yelena N. Tarasenko, Betty T. Dixon et al. · Journal of Lower Genital Tract Disease 14 Mar 2014 18
28 Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) Fixed-Dose Combination (FDC) Compared With Ritonavir-Boosted Atazanavir (ATV/r) Plus Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC) in Treatment-Naive Women With Human Immunodeficiency Virus (HIV)-1 Infection (ARIA Study): Analyses by Race Subgroups Debbie P. Hagins, Craig Dietz, Mamta K. Jain et al. · Open Forum Infectious Diseases Open access 2016 15
29 Asthma and Respiratory Foundation NZ child and adolescent asthma guidelines: a quick reference guide. Innes Asher, David G. McNamara, Cheryl Davies et al. · PubMed Dec 2017 13
30 Impact of School Flu Vaccine Program on Student Absences Sara S. Plaspohl, Betty T. Dixon, James A. Streater et al. · The Journal of School Nursing 30 Apr 2013 12
31 Impact of treatment adherence on efficacy of dolutegravir plus lamivudine and dolutegravir plus tenofovir disoproxil fumarate/emtricitabine: pooled analysis of the GEMINI-1 and GEMINI-2 clinical studies Mounir Ait‐Khaled, Juan Sierra Madero, Vicente Estrada et al. · HIV Research & Clinical Practice Open access 16 Dec 2021 11
32 Livestock-related injuries in the Midland region of New Zealand. Mischa Tosswill, Matthew James Roskruge, Alastair David Smith et al. · PubMed 5 Oct 2018 11
33 Long-term metabolic changes with bictegravir/emtricitabine/tenofovir alafenamide or dolutegravir-containing regimens for HIV Eric S. Daar, Chloe M. Orkin, Paul Edward Sax et al. · AIDS Research and Therapy Open access 7 Apr 2025 9
34 Community advisory boards as implementation strategies to center partner and patient voice in community health centers Rebekka M. Lee, Kamini Mallick, James G. Daly et al. · Journal of Clinical and Translational Science Open access 17 Dec 2024 8
35 Patient-Reported Outcomes in the Phase III BRIGHTE Trial of the HIV-1 Attachment Inhibitor Prodrug Fostemsavir in Heavily Treatment-Experienced Individuals Sarah‐Jane Anderson, Miranda I. Murray, David F Cella et al. · Patient Open access 28 Jun 2021 8
36 Final efficacy and safety of twice-yearly subcutaneous lenacapavir in treatment-naive people with HIV Debbie P. Hagins, Mezgebe Berhe, Gordon E. Crofoot et al. · AIDS 6 Oct 2025 7
37 LB4. A Phase 3, Randomized, Controlled Clinical Trial of Bictegravir in a Fixed-Dose Combination, B/F/TAF, vs. ABC/DTG/3TC in Treatment-Naïve Adults at Week 96 David Alain Wohl, Yazdan Yazdanpanah, Axel Baumgarten et al. · Open Forum Infectious Diseases Open access Nov 2018 7
38 Building Capacity to Support and Study QI in Local Georgia Public Health Systems William C. Livingood, Nandi A. Marshall, Angela H. Peden et al. · UKnowledge (University of Kentucky) Open access 2012 7
39 1985. A Prospective, Randomized Trial to Assess a Protease Inhibitor–based Regimen Switch Strategy to Manage Integrase Inhibitor–related Weight Gain William R. Short, Moti N. Ramgopal, Debbie P. Hagins et al. · Open Forum Infectious Diseases Open access 27 Nov 2023 6
40 Subcutaneous Lenacapavir in People With Multidrug-Resistant HIV-1: 156 Week Results of the CAPELLA Study Onyema Ogbuagu, ANDREW A. WIZNIA, Joseph P. McGowan et al. · Open Forum Infectious Diseases Open access 16 Dec 2025 5
41 Impact of Treatment Adherence on Efficacy of Dolutegravir + Lamivudine and Dolutegravir + Tenofovir Disoproxil Fumarate/Emtricitabine: Pooled Week 144 Analysis of the GEMINI-1 and GEMINI-2 Clinical Studies Eva Fernvik, Juan Sierra Madero, Núria Espinosa et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes 18 Oct 2023 5
42 Immunization Registries: Provider Recruitment and Participation Marianne Pappas, Barbara Baker, Debbie Appelbaum et al. · American Journal of Preventive Medicine Mar 1997 5
43 ‘I Will Not Leave My Baby Behind’: A Cook Island Māori Family's Experience of New Zealand Māori Traditional Healing Wiremu NiaNia, Tere, Allister Bush et al. · Australian and New Zealand Journal of Family Therapy Mar 2013 5
44 The Surgical Sisterhood – The Experiences of wāhine Māori and Pasifika Aspiring Surgeons Senitila Tutone, Atua Fuimaono-Asafo, Ailsa Wilson et al. · Qualitative Health Research 20 Dec 2022 4
45 155. Long-Acting Subcutaneous Lenacapavir in People with Multi-Drug Resistant HIV-1: 3-Year Results of the CAPELLA Study Onyema Ogbuagu, Joseph P. McGowan, Ann E. Stapleton et al. · Open Forum Infectious Diseases Open access 29 Jan 2025 3
46 1251. 5-year outcomes of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) as initial treatment of HIV-1 in adults with high baseline HIV-1 RNA and/or low CD4 count in two Phase 3 randomized clinical trials Moti N. Ramgopal, Anson K Wurapa, Axel Baumgarten et al. · Open Forum Infectious Diseases Open access Dec 2022 3
47 Diagnostic Chelation Challenge with DMSA: A Biomarker of Long-Term Mercury Exposure? Howard Frumkin, Claudine C. Manning, Phillip L. Williams et al. · Environmental Health Perspectives Open access Feb 2001 3
48 A cutaneous rash with mixed gell coombs allergic features, sclerodermoid changes and status post previous therapy Ana María Abreu Vélez, Josepha Devaro, Michael S. Howard · Our Dermatology Online Open access 2 Oct 2017 3
49 A Simulated-Field Method of Testing Residual Insecticide Deposits Against Cockroaches1 Arthur D. Flynn, H. F. Schoof · Journal of Economic Entomology Feb 1966 3
50 1046. Week 48 Outcomes from the BRAAVE 2020 Study: A Randomized Switch to B/F/TAF in African American Adults with HIV Debbie P. Hagins, Princy N. Kumar, Michael S. Saag et al. · Open Forum Infectious Diseases Open access Oct 2020 2

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.